...
【24h】

A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease

机译:rhoa-yap-c-myc信号轴促进了多囊肾疾病的发展

获取原文
获取原文并翻译 | 示例
           

摘要

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder caused by mutations in PKD1 or PKD2 and affects one in 500-1000 humans. Limited treatment is currently available for ADPKD. Here we identify the Hippo signaling effector YAP and its transcriptional target, c-Myc, as promoters of cystic kidney pathogenesis. While transgenic overexpression of YAP promotes proliferation and tubule dilation in mouse kidneys, loss of YAP/TAZ or c-Myc suppresses cystogenesis in a mouse ADPKD model resulting from Pkdl deficiency. Through a comprehensive kinase inhibitor screen based on a novel three-dimensional (3D) culture of Pkdl mutant mouse kidney cells, we identified a signaling pathway involving the RhoGEF (guanine nucleotide exchange factor) LARG, the small GTPase RhoA, and the RhoA effector Rho-associated kinase (ROCK) as a critical signaling module between PKD1 and YAP. Further corroborating its physiological importance, inhibition of RhoA signaling suppresses cystogenesis in 3D culture of Pkdl mutant kidney cells as well as Pkdl mutant mouse kidneys in vivo. Taken together, our findings implicate the RhoA-YAP-c-Myc signaling axis as a critical mediator and potential drug target in ADPKD.
机译:常染色体显性多囊肾病(ADPKD)是由PKD1或PKD2突变引起的遗传疾病,并影响500-1000人中的一个。适用于ADPKD的有限处理。在这里,我们识别河马信号效应yap及其转录靶,C-myc,作为囊性肾病发病机构的启动子。虽然yap的转基因过表达促进小鼠肾脏中的增殖和小管扩张,但YAP / TAZ或C-MYC的损失抑制了由PKDL缺乏导致的小鼠ADPKD模型中的囊血。通过基于新型三维(3D)培养的PKDL突变小鼠肾细胞的综合激酶抑制剂筛网,我们鉴定了一种涉及Rhogef(鸟嘌呤核苷酸交换因子)Larg,小GTPaseRhoA和rhOA效应rho的信号通路 - 作为PKD1和YAP之间的关键信令模块的缓和激酶(岩石)。进一步证实其生理重要性,抑制RhOA信号传导抑制PKDL突变体肾细胞3D培养中的囊体,以及体内PKDL突变小鼠肾脏。我们的发现结合在一起,使RhoA-YAP-C-Myc信号轴呈现为ADPKD中的临界介质和潜在的药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号